| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Jasmonic acid targets the jasmonate signaling pathway in plants, inducing MAP kinase cascades, calcium channels, and interactions with signaling molecules; in mammalian cells, it modulates cell cycle and apoptosis pathways.
|
|---|---|
| ln Vitro |
In vitro, Jasmonic acid inhibits the growth of Lepidium sativum cress roots with a 50% inhibition rate at 5×10⁻⁵ mol/L after 40 hours; it induces apoptosis in cancer cell lines and inhibits tumor cell proliferation.
|
| ln Vivo |
In vivo, Jasmonic acid exhibits anticancer activity in animal models by inhibiting tumor growth; as a plant hormone, it regulates plant defense responses, wound healing, and developmental processes; its signaling induces expression of defense-related genes.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assay: Jasmonic acid binding to its receptor (COI1-JAZ co-receptor complex in plants) is studied using surface plasmon resonance or isothermal titration calorimetry; competitive binding assays with labeled jasmonoyl-isoleucine are performed using recombinant receptor proteins to determine affinity constants.
|
| Cell Assay |
Cellular assays: Plant cell cultures (e.g., Arabidopsis or tobacco) are treated with Jasmonic acid; reporter gene assays using JAZ promoter-driven luciferase or GUS are used to monitor pathway activation; in mammalian cancer cell lines, cell viability (MTT assay), apoptosis (Annexin V staining), and cell cycle progression (flow cytometry) are assessed following treatment.
|
| Animal Protocol |
In vivo animal experiments: Jasmonic acid is administered to tumor-bearing mice via intraperitoneal or oral routes; tumor volume and weight are measured; apoptosis markers (e.g., caspase-3 activation) and proliferation markers (e.g., Ki-67) are evaluated in tumor tissues; toxicity and body weight changes are monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties: Jasmonic acid is a small lipophilic molecule with moderate oral bioavailability; it is metabolized by conjugation and β-oxidation pathways; its plasma half-life and tissue distribution vary by species; pharmacokinetic studies are limited compared to its plant biology applications.
|
| Toxicity/Toxicokinetics |
Toxicological profile: Jasmonic acid is considered relatively non-toxic to mammals at low doses; high doses may cause mild gastrointestinal irritation; it is classified as a plant growth regulator and is not approved as a pharmaceutical; standard laboratory safety precautions apply.
|
| References | |
| Additional Infomation |
Jasmonic acid is an oxomonocarboxylic acid, a compound in which (3-oxocyclopentyl)acetic acid is substituted at the 2-position of the cyclopentane ring with a (2Z)-pent-2-en-1-yl group. It is a plant metabolite belonging to the jasmonic acid ester class. It is the conjugate acid of jasmonic acid (1-) and also the enantiomer of (+)-jasmonic acid. Jasmonic acid has been reported to exist in Gelidium latifolium, Fusarium fujikuroi, and other organisms with relevant data.
Other information: Jasmonic acid is a natural product found in plants; it exists as a racemic mixture or as the (-)-enantiomer; it is used in plant physiology research to study stress responses and development; its anticancer activity is an area of ongoing investigation. |
| Molecular Formula |
C12H18O3
|
|---|---|
| Molecular Weight |
210.27
|
| Exact Mass |
210.126
|
| CAS # |
6894-38-8
|
| Related CAS # |
(±)-Jasmonic acid;77026-92-7
|
| PubChem CID |
5281166
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.061g/cm3
|
| Boiling Point |
358.1ºC at 760 mmHg
|
| Flash Point |
184.6ºC
|
| Index of Refraction |
1.49
|
| LogP |
2.412
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
15
|
| Complexity |
268
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC/C=C\C[C@@H]1[C@H](CCC1=O)CC(=O)O
|
| InChi Key |
ZNJFBWYDHIGLCU-HWKXXFMVSA-N
|
| InChi Code |
InChI=1S/C12H18O3/c1-2-3-4-5-10-9(8-12(14)15)6-7-11(10)13/h3-4,9-10H,2,5-8H2,1H3,(H,14,15)/b4-3-/t9-,10-/m1/s1
|
| Chemical Name |
2-[(1R,2R)-3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7558 mL | 23.7790 mL | 47.5579 mL | |
| 5 mM | 0.9512 mL | 4.7558 mL | 9.5116 mL | |
| 10 mM | 0.4756 mL | 2.3779 mL | 4.7558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
